Clinical and Translational Medicine
CDO1 as a prognostic biomarker and therapeutic target in gastric cancer: Mechanistic insights into the PI3K/AKT‐THBS1 axis and epigenetic reactivation by decitabine
Abstract Background As a pivotal metabolic enzyme, cysteine dioxygenase type 1 (CDO1) exerts tumour‐suppressive effects across diverse tumour types, and its expression is strongly correlated with clinical prognosis. However, the molecular mechanisms underlying CDO1‐mediated tumour suppression in gastric cancer (GC), its relationship with the tumour‐associated immune microenvironment, and pharmacological strategies to restore its expression remain poorly understood. Methods CDO1 expression and prognosis were evaluat …